Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial abstract · §3

DSIP-HIST-SLEEP — results

Primary endpoint, absolute and relative effect where derivable, and harms as reported.

Document identifier
CEI-TR-0127/3
Series
Trial abstract
Version
1.3
Published
26 Jan 2024
Last reviewed
26 Apr 2024
Next review
26 Apr 2026
Identifier
10.71829/cei.trial.127
Certainty
Not rated
Cycle
2024 Q1
Phase
Not applicable
Status
No retrievable report

§3Results

§3.1Primary endpoint

Table 3. Primary endpoint as reported.

EndpointResult as reportedCertainty
Sleep architecture measured by polysomnographyHistorical crossover studies in small samples reported inconsistent effects on sleep architecture. No modern controlled trial has been identifiedNot rated
Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed.

§3.2Endpoint hierarchy

§3.3Harms as reported

Table 5. Adverse events for DSIP from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.

EventActive, %Comparator, %Source trial
No controlled safety datasetNone of adequate quality exists
Injection-site reactionReported anecdotally
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.